Standardmuscle-building

Ipamorelin

Ipamorelin is a synthetic peptide composed of five amino acids, formally classified as a Growth Hormone Secretagogue (GHS). Its name is derived from the intention of its development. Ipamorelin peptide was designed to act via ghrelin receptor binding. The ghrelin receptors on the pituitary gland are also known as Growth Hormone Secretagogue receptors (GHS-R), and through its implied action, Ipamorelin may host the potential to trigger the GHS-Rs on the pituitary gland and potentially stimulate the release of growth hormone. Ipamorelin is the first synthetic GHS that appears highly selective and may have the potential to augment the production of hGH without affecting other pituitary hormones such as prolactin or adrenocorticotropic hormone (ACTH). The potential increase in hGH might promote lipolysis and insulin-like growth factor-1 (IGF-1) production synthesis. Consequently, IGF-1 may become a mediator of hGH's anabolic actions, and thereby the peptide may act to increase cellular proliferation and bone and muscle anabolism.

Size

$63.00 USD/ 10mg

Technical Specifications

Technical specifications for Ipamorelin
Sequence	Aib-His-D-2Nal-D-Phe-Lys-NH2
Molecular Formula	C38H49N9O5
Molecular Weight	711.86 g/mol
Purity	≥99% (HPLC)
Form	Lyophilized powder
Storage	-20°C, desiccated
CAS	170851-70-4
Also Known As	NNC 26-0161

Application Areas

Tendon and ligament healing studies

Muscle injury recovery protocols

Gastrointestinal tissue repair research

Anti-inflammatory pathway research

Wound healing research

Veterinary wound healing applications

COA Verified

Fast Shipping

Secure Payment

For Research Use Only. Products are not for human or veterinary consumption. Not a drug, dietary supplement, or medical device. Sold exclusively to qualified research professionals.

Bio-Engineered Precision

Ipamorelin is the first synthetic GHS that appears highly selective and may have the potential to augment the production of hGH without affecting other pituitary hormones such as prolactin or adrenocorticotropic hormone (ACTH). The potential increase in hGH might promote lipolysis and insulin-like growth factor-1 (IGF-1) production synthesis. Consequently, IGF-1 may become a mediator of hGH's anabolic actions, and thereby the peptide may act to increase cellular proliferation and bone and muscle anabolism.

Purity Level≥99% (HPLC)

Molecular Weight711.86 g/mol

Molecular FormulaC38H49N9O5

SequenceAib-His-D-2Nal-D-Phe-Lys-NH2

Ipamorelin Peptide and Selective Agonism

Based on one 1998 murine model-based research study, researchers suggested that Ipamorelin may release growth hormones from the pituitary cells. When Ipamorelin was presented to swine and pentobarbitone anesthetized rats, it reportedly exhibited release in growth hormones. The researchers hypothesized that Ipamorelin may be a growth receptor agonist stimulating GH release through potential affinity in growth hormone receptors.

Key Observations

The researchers commented that Ipamorelin appears to be the first GHS-R agonist with a selectivity for GH release similar to that displayed by GHRH. Scientific research studies have also suggested that Ipamorelin may lead to increased hGH secretion, possibly without significantly affecting other pituitary hormones such as prolactin or ACTH, making it a highly selective tool for GH research.

Ipamorelin Peptide and Growth Hormone Synthesis

Studies conducted in vitro suggest that the interaction of Ipamorelin with GHS receptors may potentially affect somatotroph cells in the anterior pituitary gland by triggering a series of cellular signaling events. This theorized pathway involves the activation of phospholipase C (PLC), which may lead to the increased release of inositol triphosphate (IP3) and diacylglycerol (DAG), stimulating calcium ion release and activating protein kinase C (PKC).

Key Findings

In a clinical trial in 1999, Ipamorelin was presented every 15 minutes for a set period to eight test subjects. Two hours post-study, the levels of growth hormone had apparently increased, with Ipamorelin tending to boost growth hormone levels to as much as 80 mIU/L (roughly 26.6 ng/mL). When compared to a placebo (baseline of 1.31 mIU/L), the enhancement appeared to have exceeded a 60-fold uplift.

Ipamorelin Peptide and Bone Tissue

It is conceivable that Ipamorelin may positively influence bone mineral density. The theory posits that Ipamorelin might stimulate osteoblasts via hGH-mediated mechanisms, potentially leading to their enhanced proliferation, growth, and specialization. In a study, murine models were exposed to either Ipamorelin or a placebo, with the impact on bone mineral density monitored through real-time dual X-ray absorptiometry (DEXA) assessments at critical sites including the femur and L6 vertebra.

Study Design

Preliminary findings implied that the peptide may have contributed to increased body mass and a probable elevation in overall tibial and vertebral BMC as detected by DEXA compared to the placebo group. The pQCT data appeared to suggest that the observed augmentation in cortical BMC may have stemmed from an enlargement in the cross-sectional area of the bone, while cortical volumetric bone mineral density appeared to remain steady.

Ipamorelin Peptide and Nitrogen Balance

Researchers have suggested that Ipamorelin may potentially mediate anabolic action, assessed through its impact on nitrogen balance. In a distinct investigation, researchers aimed to explore the action of Ipamorelin on specific liver markers associated with alpha-amino-nitrogen conversion during induced catabolic states, focusing on the liver's capacity to synthesize urea-N as an indicator of the organ's ability to process nitrogen.

Key Findings

The findings suggested that Ipamorelin might have contributed to a possible 20% reduction in CUNS compared to the artificially induced catabolic condition. Furthermore, it might have diminished the expression of urea cycle enzymes, possibly restored nitrogen balance, and in theory altered or improved nitrogen concentrations in different organs, suggesting a potential anabolic effect in catabolic states.

Certificates & Testing

Batch-level purity documentation

Every P3X Labs batch is independently tested by a third-party laboratory. COA documents confirm purity, identity, and absence of contaminants. Lot-specific COAs are linked to each shipment via QR code on the vial label.

COA: assigned at fulfillment — scan QR on vial

HPLC tested

Mass spectrometry verified

≥99% purity guaranteed